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Abstract. The activation of a β-class carbonic anhydrase (CAs, EC 4.2.1.1) from Leishmania 
donovani chagasi (LdcCA) was investigated using a panel of natural and non-natural amino acids 
and amines. The most effective activators belonged to the amine class, with histamine, dopamine, 
serotonin, 2-pyridyl-methylamine and 4-(2-aminoethyl)-morpholine with activation constants in the 
range of 0.23 – 0.94 µM. In addition, 2-(2-aminoethyl)pyridine and 1-(aminoethyl)-piperazine were 
even more effective activators (KAs of 9-12 nM). Amino acids such as L-/D-His, L-/D-Phe, L-/D-
DOPA, L-/D-Trp and L-/D-Tyr were slightly less effective activators compared to the amines, but 
showed activation constants in the low micromolar range (1.27 – 9.16 µM). Many of the investigated 
activators are autacoids that are present in rather high concentrations in different tissues of the host 
mammals infected by these parasites. As CA activators have not yet been investigated for protozoan 
CAs, this study may be relevant for an improved understanding of the role of this enzyme in the life 
cycle of Leishmania. 
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1. Introduction 
 
 Leishmaniasis is a rather diffuse sub-tropical disease provoked by protozoan belonging to 
Leishmania spp.1,2 There are multiple forms of this disease, among which the visceral (VL), caused 
by L. infantum and L. donovani, as well as the tegumentary forms of the disease, which may include 
the cutaneous (CL), diffuse (DCL), and muco-cutaneous (MCL) leishmaniases.1,2 The disease is 
transmitted by sand flies, and the life cycle of the pathogen is rather complex, as one of its 
developmental forms, the amastigote, dwells within immunological cells of the host, making its 
targeting by the immune system or by drugs rather challenging.1,2 There are limited available drugs 
to treat this condition, and many strains of the parasite are increasingly resistant to drug treatment. 
Pentavalent antimonium salts (such as sodium stibogluconate, used via the parenteral route), the 
orally available miltefosine, or parenterally used paromomycin, and amphotericin B, show various 
degrees of resistance worldwide.1,2 Thus, there is a strong need to design alternative therapies and to 
understand in more detail the life cycle of the parasite and its interactions with the mammalian host. 
Recently, we have proposed protozoan carbonic anhydrases (CAs, EC 4.2.1.1) as potential targets for 
dealing with this problem, showing that in L. donovani chagasi,3,4 Trypanosoma cruzi, 5-7 or 
Plasmodium falciparum,8-11 members of this family of enzymes are present, and that their inhibition 
interferes with the growth of the parasites in vitro and in vivo.2-11 L. donovani chagasi encodes for a 
β-class CA (denominated LdcCA),3 T. cruzi for an α-CA (TcCA),5 and in P. falciparum, a new genetic 
family of these enzymes, the η-CA class has been discovered (PfaCA).8 These three protozoans thus 
encode CAs belonging to three different genetic families, which suggests that their detailed 
investigation may lead to the discovery of potential drug targets with activities that can be selectively 
modulated for the management of the diseases they provoke. However, in contrast to the CA 
inhibitors (CAIs), were shown to inhibit the growth of these protozoan species, investigation of the 
CA activators (CAAs) have been limited.12,13 Such compounds participate to the CA catalytic cycle, 
which is shown schematically in Equations 1 and 2 (where ‘E’ denotes enzyme): 
     H2O 
EZn2+OH- + CO2 ⇔ EZn2+HCO3- ⇔ EZn2+-OH2  +  HCO3-    (1) 
EZn2+-OH2 ⇔ EZn2+OH-  +  H+                                                    (2) 
The first step involves a zinc-bound hydroxide species of the enzyme nucleophilically 
attacking a CO2 substrate that is bound in a hydrophobic pocket nearby in an optimal orientation for 
the hydration reaction (Equation 1).14,15 Bicarbonate formed in the hydration reaction replaced by an 
incoming water molecule to generate the catalytic acid form of the enzyme, EZn2+OH2 (Equation 
1). For the regeneration of the zinc hydroxide species, a proton transfer reaction occurs from the 
Zn(II)-bound water molecule to the external medium (Equation 2), which is the rate-determining step 
of the entire catalytic cycle. 
EZn2+-OH2  + A⇔[EZn2+-OH2 - A] ⇔[EZn2+OH- - AH+]⇔ EZn2+OH- + AH+     (3) 
    enzyme - activator complexes 
In the presence of activators (A in Equation 3), the formation of enzyme-activator complexes 
occurs, in which the proton transfer reaction becomes intramolecular and thus, more efficient than 
the corresponding intermolecular process.14,15 This mechanism of CA activation was demonstrated 
by kinetic and crystallographic studies for the human isoforms hCA I and II.16 Based on crystal 
structures, the activator was bound at the entrance to the active site cavity. Most of the activators 
belong to the amino and/or amino acid chemotypes, and possess moieties with an appropriate pKa 
(generally in the range of 6-8) for efficient proton shuttling processes between the active site and the 
environment.14-16  
CAAs belonging to various classes were extensively investigated for the activation of all 
mammalian (human) CA isoforms known to date, hCA I – XIV.17-21 Several drug design studies for 
CAAs belonging to the amine and amino acid classes have also been reported, and led to the discovery 
of the activation profile of the different isoforms with several classes of activators.17-21 Recently, the 
potential of this class of pharmacological agents for the therapy of memory disorder and cognition 
impairment has also been demonstrated.22 However, unlike CAIs, which are clinically used as 
diuretics,23 antiglaucoma drugs,24 antiobesity,25 antitumor,26 anti-neuropathic pain,27 or anti-arthritis 
agents,28 there are no clinically approved CAAs. Natural and non-natural amino acids and amines of 
type 1-19 are among the most investigated simple CAAs, and they were evaluated in the present study 
(Fig. 1). These compounds were investigated for their potential as CAAs against many classes of 
CAs, including a limited number of bacterial CAs.29 However, no protozoan CA enzymes have been 
investigated for their activation to date. Here we report the first activation study of LdcCA, the β-
class enzyme from the protozoan, L. donovani chagasi, one of the causative agents of visceral 
leishmaniasis. 
 
2. Results and Discussion 
To confirm that the activator binds to a different site than the substrate, the effect of the presence of 
L-Trp on the enzyme kinetics was investigated (Table 1). We have chosen this amino acid 
derivatives for the detailed kinetic studies due to the fact that it is a rather effective activator of 
many CAs, and its X-ray crystal structure in adduct with hCA II has also been reported.13 
Furthermore, this amino acid is present in rather high concentrations in many tissues in vertebrates, 
including humans, being the precursor of important autacoids/neurotransmitters such as serotonin.13 
The Km value does not depend on the presence of L-Trp. In contrast, kcat depends strongly on the 
presence of L-Trp. For example, the use of 10 µM L-Trp resulted in the kcat of LdcCA increasing 
by 3.05 times than without the activator (Table 1). These data are as expected, and confirm that the 
activator is not binding to the same site as the substrate, which has been documented by X-ray 
crystallography for the human enzymes.13,16a Moreover, L-Trp is a more effective towards LdcCA 
than the human enzymes used for comparison purposes. 
 
Table 1: Activation of human carbonic anhydrase (hCA) isozymes I, II, and LdcCA with L-Trp, at 
25°C, for the CO2 hydration reaction.30  
Isozyme  kcat*  KM*  (kcat)L-Trp**  KA*** (µM) 
   (s-1)  (mM)  (s-1)   L-Trp 
hCA Ia   2.0x105 4.0  3.4x105  44.0 
hCA IIa  1.4x106 9.3  4.9x106  27.0 
LdcCAb  9.35×105 15.8  28.6×105  4.02 
_______________________________________________________________________________ 
* Observed catalytic rate without activator. KM values in the presence and the absence of activators were the 
same for the various CAs (data not shown). 
** Observed catalytic rate in the presence of 10 µM activator. 
*** The activation constant (KA) for each enzyme was obtained by fitting the observed catalytic 
enhancements as a function of the activator concentration.13 Mean from at least three determinations by a 
stopped-flow, CO2 hydrase method.30 Standard errors were in the range of 5-10 % of the reported values 
(data not shown). 
aHuman recombinant isozymes, from ref.13; b Protozoan recombinant enzyme, this work. 
 
The structure-activity relationship (SAR) for the activation of LdcCA with compounds 1-19, 
can be delineated considering the data shown in Table 2, where the activation data of the human 
isoforms hCA I and II are also presented for comparison. 
 All amino acids and amines investigated act as efficient LdcCA activators, with activation 
constants that range from the low nanomolar (9 nM for 17) to the micromolar (15.9 µM for 11). 
Amines are generally more effective activators compared to the amino acids, except for L-adrenaline 
19 (the only secondary amine investigated here) which has the same potency as most of the amino 
acids (KA of 4.89 µM). The most effective LdcA activators were aminopyridine 16 and piperazine 17 
(KAs of 9 – 12 nM), which incorporate a heterocyclic ring and the aminoethyl moiety (both of which 
can participate in proton transfer reactions between the zinc coordinated water and the external 
milieu). Amines 12-15 and 18, structurally related to the most effective activators discussed above, 
also show an interesting and efficient activating profile, with KAs ranging between 0.23 and 0.94 µM. 
Thus, the SAR here is rather well defined, with all these compounds possessing the aminoethyl- or 
aminomethyl tails appended to an aromatic or heterocyclic moiety. X-ray crystallography for adducts 
of some of these derivatives with hCA I or II showed that both these fragments of the activator are 
participating to the stabilization of the enzyme-activator complex, by forming hydrogen bonds and 
hydrophobic interaction with amino acid residues at the entrance of the active site cavity.13,16 
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Fig. 1: Amino acids 1-11 and amines 12-19 investigated as LdcCA activators. 
 
Table 2: Activation constants of hCA I, hCA II and the protozoan enzyme LdcCA with amino acids 
and amines 1 – 19. Data for hCA I and II are from ref.13 
No. Compound     KA (µM)*  
     hCA Ia  hCA IIa  LdcCAb 
1 L-His    0.03  10.9   8.21 
2 D-His    0.09  43   4.13 
3 L-Phe    0.07  0.013   9.16 
4 D-Phe    86  0.035   3.95 
5 L-DOPA   3.1  11.4   1.64 
6 D-DOPA   4.9  7.8   5.47 
7 L-Trp    44  27   4.02 
8 D-Trp    41  12   6.18 
9 L-Tyr    0.02  0.011   8.05 
10 D-Tyr    0.04  0.013   1.27 
11 4-H2N-L-Phe   0.24  0.15   15.9 
12 Histamine   2.1  125   0.74 
13 Dopamine   13.5  9.2   0.81 
14 Serotonin   45  50   0.62 
15 2-Pyridyl-methylamine 26  34   0.23 
16 2-(2-Aminoethyl)pyridine 13  15   0.012 
17 1-(2-Aminoethyl)-piperazine 7.4  2.3   0.009 
18 4-(2-Aminoethyl)-morpholine 0.14  0.19   0.94 
19 L-Adrenaline   0.09  96   4.89 
* Mean from three determinations by a stopped-flow, CO2 hydrase method.30 Standard 
errors were in the range of 5-10 % of the reported values (data not shown). 
a Human recombinant isozymes, stopped flow CO2 hydrase assay method;13,30 
 bThis work. 
 
 The amino acids 1-10 were slightly less effective as LdcCA activators compared to the amines 
discussed above, with KAs ranging between 1.27 and 15.9 µM. In several cases (D-His, D-Phe, D-
Tyr), the D-enantiomer was more efficient as LdcCA activator compared to the corresponding L-
enantiomer, whereas for the DOPA and Trp, the L-enantiomers were the more effective activators 
compared to the corresponding D-amino acids (Table 1). Small changes in the scaffold of the activator 
lead to important differences of activity: replacement of the phenolic OH from L-Tyr (9) by an amine 
moiety (as in 11) lead to an almost 2-fold loss of activating properties. 
 The activation of the protozoan enzyme was rather different from that of the α-class enzymes 
hCA I and II. For example, L-/D-Tyr were highly effective, nanomolar hCA I and II activators, 
whereas their effects on LdcCA are seen only at micromolar concentrations. On the contrary, amine 
16 may be considered as a LdcCA – selective activator, with a KA of 12 nM for the protozoan enzyme 
and of 13-15 µM for the human CAs. Thus, this compound may be used as a pharmacologic tool to 
explore the role that LdcCA might play in the life cycle of this protozoan and whether CA activation 
is important for the infection or host colonization by Leishmania, in diverse phases of the pathogen’s 
life cycle. 
 
3. Conclusions 
The first activation study of a protozoan CA is reported here. The β-class enzyme from Leishmania 
donovani chagasi (LdcCA) was investigated for its interaction with a panel of natural and non-natural 
amino acids and amines acting as CAAs of mammalian and bacterial enzymes. Nanomolar activators 
were identified that belong to the amine class, with histamine, dopamine, serotonin, 2-pyridyl-
methylamine and 4-(2-aminoethyl)-morpholine (activation constants of 0.23 to 0.94 µM). The most 
effective activators were 2-(2-aminoethyl)pyridine and 1-(aminoethyl)-piperazine which had KAs of 
9-12 nM. Amino acids such as L-/D-His, L-/D-Phe, L-/D-DOPA, L-/D-Trp and L-/D-Tyr were less 
effective activators compared to the amines, but showed activation constants in the low micromolar 
range (1.27 – 9.16 µM). Because activators have not been identified for protozoan CAs, this study 
should be important for understanding the role that this enzyme has in the life cycle of Leishmania, 
particularly considering the fact that many of the activators identified are autacoids present in rather 
high concentrations in different tissues of the host mammals that are infected by these parasites. 
 
4. Experimental 
 
4.1. Chemistry. Amino acids and amines 1-19 were commercially available, highest purity reagents 
from Sigma-Aldrich, Milan, Italy. LdcCA was a recombinant protein produced as reported earlier by 
our group.3 
 
4.2. CA enzyme activation assay 
An Sx.18Mv-R Applied Photophysics (Oxford, UK) stopped-flow instrument has been used to assay 
the catalytic activity of various CA isozymes for CO2 hydration reaction.30 Phenol red (at a 
concentration of 0.2 mM) was used as indicator, working at the absorbance maximum of 557 nm, 
with 10 mM Hepes (pH 7.5) or TRIS (pH 8.3) as buffers, 0.1 M Na2SO4 (for maintaining constant 
ionic strength), following the CA-catalyzed CO2 hydration reaction for a period of 10 s at 25 ◦C. 
Activity of the α-CAs was measured at pH 7.5 whereas that of the β-class enzymes at pH 8.3 in order 
to avoid the possibility that their active site is closed.3,12 The CO2 concentrations ranged from 1.7 to 
17 mM for the determination of the kinetic parameters and activation constants. For each activator at 
least six traces of the initial 5-10% of the reaction have been used for determining the initial velocity. 
The uncatalyzed rates were determined in the same manner and subtracted from the total observed 
rates. Stock solutions of activators (10 mM) were prepared in distilled-deionized water and dilutions 
up to 1 nM were done thereafter with the assay buffer. Activator and enzyme solutions were pre-
incubated together for 15 min (standard assay at room temperature) prior to assay, in order to allow 
for the formation of the E–A complex. The activation constant (KA), defined similarly with the 
inhibition constant KI, can be obtained by considering the classical Michaelis–Menten equation 
(equation 4), which has been fitted by non-linear least squares by using PRISM 3: 
   v =vmax/{1+KM/[S](1+[A]f/KA)}                                              (4) 
where [A]f is the free concentration of activator. 
Working at substrate concentrations considerably lower than KM ([S] <<KM), and considering that 
[A]f can be represented in the form of the total concentration of the enzyme ([E]t)and activator ([A]t), 
the obtained competitive steady-state equation for determining the activation constant is given by 
equation 5: 
          v=v0.KA/{KA+([A]t-0.5{([A]t+[E]t+KA)-([A]t+[E]t+KA)2-4[A]t.[E]t)1/2}}     (5) 
where v0 represents the initial velocity of the enzyme-catalyzed reaction in the absence of 
activator.12,13,16 
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